PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

PFS

ADJUSTMENTS

Quality of life

QoL data pending

Serious and disabling adverse effects

Other adjustments

Amivantamab + lazertinib MARIPOSA

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

3

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: FDA: Amivantamab in combination with lazertinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. EMA: Amivantamab in combination with lazertinib is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
Experimental Arm: Amivantamab + lazertinib
Control Arm: Osimertinib